{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:53:11Z","timestamp":1768323191740,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06192-9","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:22:24Z","timestamp":1768299744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004)"],"prefix":"10.1007","volume":"44","author":[{"given":"Georges","family":"Mjaess","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Quackels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Fantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Tricard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Carnot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Sideris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves Martinez","family":"Chanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Diamand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Roumegu\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"1","key":"6192_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3233\/BLC-201511","volume":"8","author":"R Benkhadra","year":"2022","unstructured":"Benkhadra R, Nayfeh T, Patibandla SK, Peterson C, Prokop L, Alhalabi O et al (2022) Systematic review and Meta-Analysis of cisplatin based neoadjuvant chemotherapy in muscle invasive bladder cancer. Bladder Cancer Amst Neth 8(1):5\u201317","journal-title":"Bladder Cancer Amst Neth"},{"issue":"5","key":"6192_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","volume":"18","author":"G Iyer","year":"2020","unstructured":"Iyer G, Tully CM, Zabor EC, Bochner BH, Dalbagni G, Herr HW et al (2020) Neoadjuvant Gemcitabine-Cisplatin plus radical Cystectomy-Pelvic lymph node dissection for Muscle-invasive bladder cancer: A 12-year experience. Clin Genitourin Cancer 18(5):387\u2013394","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"6192_CR3","doi-asserted-by":"publisher","first-page":"102704","DOI":"10.1016\/j.fjurol.2024.102704","volume":"34","author":"I Boutaleb","year":"2024","unstructured":"Boutaleb I, Mjaess G, Roumegu\u00e8re T (2024) Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis. Fr J Urol 34(9):102704","journal-title":"Fr J Urol"},{"issue":"4","key":"6192_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucian\u00f2 R et al (2020) Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with Muscle-invasive bladder carcinoma with variant histologies. Eur Urol 77(4):439\u2013446","journal-title":"Eur Urol"},{"issue":"11","key":"6192_CR5","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS et al (2019) Clinical efficacy and biomarker analysis of neoadjuvant Atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 25(11):1706\u20131714","journal-title":"Nat Med"},{"issue":"6","key":"6192_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.eururo.2019.12.018","volume":"77","author":"G Pignot","year":"2020","unstructured":"Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Bigot P, Werle P et al (2020) Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: A new surgical challenge? Eur Urol 77(6):761\u2013763","journal-title":"Eur Urol"},{"key":"6192_CR7","doi-asserted-by":"publisher","unstructured":"Ben-David R, Pellegrino F, Mehrazin R, Thomas J, Geduldig J, Lidagoster S et al Immunotherapy-based neoadjuvant treatment and complication rates after radical cystectomy. BJU Int [Internet]. [cited 2025 Jun 11];n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/bju.16662","DOI":"10.1111\/bju.16662"},{"issue":"5","key":"6192_CR8","doi-asserted-by":"publisher","first-page":"e012045","DOI":"10.1136\/jitc-2025-012045","volume":"13","author":"J Blanc","year":"2025","unstructured":"Blanc J, Carnot A, Barth\u00e9l\u00e9my P, Casert V, Sautois B, Van den Brande J et al (2025) Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial. J Immunother Cancer 13(5):e012045","journal-title":"J Immunother Cancer"},{"issue":"17","key":"6192_CR9","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK et al (2011) Treatment of patients with metastatic urothelial cancer unfit for Cisplatin-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 29(17):2432\u20132438","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"6192_CR10","first-page":"109543","volume":"51","author":"S Albisinni","year":"2025","unstructured":"Albisinni S, Orecchia L, Mjaess G, Aoun F, Del Giudice F, Antonelli L et al (2025) Enhanced recovery after surgery for patients undergoing radical cystectomy: surgeons\u2019 perspectives and recommendations ten years after its implementation. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 51(3):109543","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"6192_CR11","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350:g7594","journal-title":"BMJ"},{"issue":"3","key":"6192_CR12","doi-asserted-by":"publisher","first-page":"e472822","DOI":"10.1200\/EDBK-25-472822","volume":"45","author":"MJ Ribal","year":"2025","unstructured":"Ribal MJ, Rosenberg J, Ajami T, Vilaseca A, Xia L, Sternschuss M et al (2025) Advancing perioperative treatment options for localized Muscle-Invasive bladder cancer: A step forward. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 45(3):e472822","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"issue":"1","key":"6192_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00345-024-05361-y","volume":"43","author":"G Pignot","year":"2025","unstructured":"Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G et al (2025) The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma. World J Urol 43(1):54","journal-title":"World J Urol"},{"issue":"1","key":"6192_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11701-024-01850-9","volume":"18","author":"DP McNicholas","year":"2024","unstructured":"McNicholas DP, El-Taji O, Siddiqui Z, Hanchanale V (2024) Systematic review comparing uretero-enteric stricture rates between open cystectomy with ileal conduit, robotic cystectomy with extra-corporeal ileal conduit and robotic cystectomy with intra corporeal ileal conduit formation. J Robot Surg 18(1):100","journal-title":"J Robot Surg"},{"key":"6192_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.euros.2023.01.009","volume":"50","author":"S Tappero","year":"2023","unstructured":"Tappero S, Dell\u2019Oglio P, Cerruto MA, Sanchez Salas R, Buisan Rueda O, Simone G et al (2023) Ileal conduit versus orthotopic neobladder urinary diversion in Robot-assisted radical cystectomy: results from a Multi-institutional series. Eur Urol Open Sci 50:47\u201356","journal-title":"Eur Urol Open Sci"},{"key":"6192_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.urology.2016.06.034","volume":"96","author":"J Crozier","year":"2016","unstructured":"Crozier J, Hennessey D, Sengupta S, Bolton D, Lawrentschuk N (2016) A systematic review of ileal conduit and neobladder outcomes in primary bladder cancer. Urology 96:74\u201379","journal-title":"Urology"},{"issue":"21","key":"6192_CR17","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1001\/jama.2022.7393","volume":"327","author":"JWF Catto","year":"2022","unstructured":"Catto JWF, Khetrapal P, Ricciardi F, Ambler G, Williams NR, Al-Hammouri T et al (2022) Effect of Robot-Assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-Day morbidity and mortality among patients with bladder cancer: A randomized clinical trial. JAMA 327(21):2092\u20132103","journal-title":"JAMA"},{"issue":"5","key":"6192_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.acuro.2022.11.003","volume":"47","author":"S Fontanet","year":"2023","unstructured":"Fontanet S, Basile G, Baboudjian M, Gallioli A, Huguet J, Territo A et al (2023) Robot-assisted vs. open radical cystectomy: systematic review and meta-analysis of randomized controlled trials. Actas Urol Esp 47(5):261\u2013270","journal-title":"Actas Urol Esp"},{"issue":"8","key":"6192_CR19","first-page":"1511","volume":"49","author":"G Mjaess","year":"2023","unstructured":"Mjaess G, Diamand R, Aoun F, Assenmacher G, Assenmacher C, Verhoest G et al (2023) Cost-analysis of robot-assisted radical cystectomy in europe: A cross-country comparison. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 49(8):1511\u20131518","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"19","key":"6192_CR20","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H et al (2024) Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 391(19):1773\u20131786","journal-title":"N Engl J Med"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06192-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06192-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06192-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:22:26Z","timestamp":1768299746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06192-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6192"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06192-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thierry Roumegu\u00e8re: Speaker for Johnsson and Johnsson, Astellas, Recordati Gauthier Marcq: Speaker for a pharmaceutical company: _BMS, MSD, Janssen, Astellas, Merck Serono. Support from a pharmaceutical company for participation in a national or international congress: _Bouchara Recordati, BMS, MSD, Janssen, Ipsen, Astellas, Photocure. Consultant: _Janssen, BMS__Principal investigator of a pharmaceutical industry trial: _MSD, Janssen, Fidia, Steba Biotech_J\u00e9r\u00e9my Blanc: FNRS funded PhD student, medical advisory (institutional) from Merck, travel support for medical congresses from Ipsen, Recordati, Merck and AstraZeneca. AC: honoraria for educational events from Astellas. Nieves Martinez Chanza: research travel from Pfizer and Ipsen, consulting fees (institutional) from BMS, Bayer and Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The rest of the authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the H\u00f4pital Universitaire de Bruxelles research ethics committee (number of ethics approval:\n                      CE2716\n                      ). The authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki. All patients have signed a written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}}],"article-number":"90"}}